English Polski
Vol 14, No 3 (2019)
Review paper
Published online: 2019-07-04

open access

Page views 1001
Article views/downloads 1742
Get Citation

Connect on Social Media

Connect on Social Media

New treatment options for the patients with metabolic syndrome

Beata Wożakowska-Kapłon1
Folia Cardiologica 2019;14(3):264-271.


The occurrence of metabolic syndrome is a risk factor for developing cardiovascular disease. Moreover, the size oflow-density lipoprotein (LDL) particles, and liver dysfunction identified as nonalcoholic fatty liver disease (NAFLD) both represent important biomarkers for the development of cardiometabolic risk in patients with metabolic syndrome. Patients being treated with bergamot polyphenolic fraction show significant reductions in fasting plasma glucose, serum LDL cholesterol and triglycerides along with an increase of high-density lipoprotein cholesterol level. This effect is accompanied in ultrasonography examination by significant reduction NAFLD.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52(5): 1210–1214.
  2. Mamcarz A, Podolec P, Kopeć G . Wytyczne Polskiego Forum Profilaktyki dotyczące zespołu metabolicznego. In: Podolec P. ed. Podręcznik Polskiego Forum Profilaktyki. Tom 2. Medycyna Praktyczna, Kraków 2010: 557–558.
  3. Barylski M, Filipiak K, Okopień B, et al. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego dotyczące miejsca standaryzowanej kompozycji polifenoli z bergamoty w terapii dyslipidemii oraz jej innego potencjalnego zastosowania. Folia Cardiol. 2018; 13(3): 222–235.
  4. Catapano AL, Graham I, Backer GD, et al. Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Miażdżycowego (EAS) do spraw leczenia zaburzeń lipidowych. Wytyczne ESC/EAS dotyczące leczenia zaburzeń lipidowych w 2016 roku. Kardiol Pol. 2016; 74(11): 1234–1318.
  5. Paszkiewicz M, Budzyńska A, Różalska B, et al. Immunomodulacyjna rola polifenoli roślinnych. Post Hig Med Dosw. 2012; 66: 637–646.
  6. Quiñones M, Miguel M, Aleixandre A. Beneficial effects of polyphenols on cardiovascular disease. Pharmacol Res. 2013; 68(1): 125–131.
  7. Mollace V, Sacco I, Janda E, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011; 82(3): 309–316.
  8. Gliozzi M, Carresi C, Musolino V, et al. The effect of bergamot-derived polyphenolic fraction on LDL small dense particles and non alcoholic fatty liver disease in patients with metabolic syndrome. Adv Biol Chem. 2014; 4(2): 129–137.
  9. Mollace V, Malara N, Gratteri S, et al. Bergamot polyphenolic fraction counteracts erectile dysfunction occurring in patients suffering from type 2 diabetes. PharmaNutrition. 2016; 4: S41–S46.
  10. Carresi C, Gliozzi M, Giancotta C, et al. Studies on the protective role of Bergamot polyphenols in doxorubicin-induced cardiotoxicity. PharmaNutrition. 2016; 4: S19–S26.
  11. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol (1985). 1999; 87(5): 1990–1995.
  12. Lauro F, Ilari S, Giancotti L, et al. The protective role of bergamot polyphenolic fraction on several animal models of pain. PharmaNutrition. 2016; 4: S35–S40.
  13. Nisticò SP, Bottoni U, Gliozzi M, et al. Bergamot polyphenolic fraction counteracts photoageing in human keratinocytes. PharmaNutrition. 2016; 4: S32–S34.